Créer jeu
Télécharger
Obtenir Plan Académique
Partager le jeu
Intégrez-le à votre plateforme

Vous pouvez intégrer le jeu dans un LMS compatible avec LTI 1.1 ou LTI 1.3 comme Canvas, Moodle ou Blackboard. Les scores seront ainsi automatiquement enregistrés dans le carnet de notes de la plateforme.
Télécharger
Vous avez dépassé le nombre maximum de jeux que vous pouvez intégrer à Google Classroom avec votre Plan actuel.

Pour intégrer autant de jeux que vous le souhaitez dans Google Classroom, vous avez besoin d’un Plan Académique ou un Plan Commerciel.

Vous avez dépassé le nombre maximum de jeux que vous pouvez intégrer à Microsoft Teams avec votre Plan actuel.

Pour intégrer autant de jeux que vous le souhaitez dans Microsoft Teams, vous avez besoin d’un Plan Académique ou un Plan Commerciel.

Le téléchargement du jeu est une fonctionnalité exclusive pour les utilisateurs avec un Plan Académique ou un Plan Commercial.

Obtenez votre Plan Académique ou Plan Commercial dès maintenant et commencez à intégrer vos jeux dans votre LMS, votre site Web ou votre blog.

Si vous le souhaitez, vous pouvez télécharger une jeu de test ici et tester son intégration:

CONSORT RCT Quick Quiz

Oui ou Non

Parties jouées 0

À propos de cette activité

Yes/No questions on CONSORT for RCTs

Créé par

India

Téléchargez la version pour jouer sur papier

Créez votre propre jeu gratuite à partir de notre créateur de jeu
Affrontez vos amis pour voir qui obtient le meilleur score dans ce jeu

Top Jeux

%
Anonyme
Anonyme
%
%
%
Vous avez dépassé le nombre maximum de jeux que vous pouvez imprimer avec votre Plan actuel.

Pour imprimer autant de jeux que vous le souhaitez, vous avez besoin d’un Plan Académique ou un Plan Commerciel.

Imprimez votre jeu
CONSORT RCT Quick Quiz
 

CONSORT RCT Quick QuizVersion en ligne

Yes/No questions on CONSORT for RCTs

par Amit Jaiswal
1

Use the word “randomised” in the title

2

Specific objectives mentioned in the summary

3

Trial design (e.g., parallel group, cluster) and framework (e.g., superiority, equivalence, non- inferiority, exploratory) mentioned in the summary

4

Eligibility criteria for participants and settings where the trial was conducted mentioned in summary

5

Intervention(s) and comparator(s) intended for each group mentioned in the summary

6

Primary outcome(s) mentioned in the summary

7

How participants were allocated to interventions (e.g., centralized computer-generated randomization) mentioned in the summary

8

Who was blinded after assignment to interventions (e.g., participants, care providers, outcome assessors) mentioned in the summary

9

Number of participants randomized to each group mentioned in the summary

10

For the primary outcome, the number of participants analysed in each group, a result for each group and the estimated effect size and its precision is mentioned in the summary

11

General interpretation of the results mentioned ion the summary

12

Name of registry, Trial registry identifying number, URL to registry record, Date of registration mentioned

13

Where the protocol and full statistical analysis plan can be accessed with URL to its location mentioned

14

Sources of funding and other support, role of funders in the design, conduct, analysis and reporting of the trial mentioned

15

Financial and other conflicts of interest of the manuscript authors mentioned

16

Scientific background and rationale mentioned in the introduction

17

Specific objectives related to benefits and harms mentioned in the introduction

18

Description of trial design including type of trial (e.g., parallel group, crossover), allocation ratio, and framework (e.g., superiority, equivalence, non-inferiority etc.) mentioned in methodology

19

Important changes to the trial after it commenced including any outcomes or analyses that were not prespecified, with reason mentioned in methodoly

20

Settings (e.g., community, hospital) and locations (e.g., countries, sites) where the trial was conducted mentioned in methodology

21

Eligibility criteria for participants including method of recruitment of participants (eg. referral, self selection or advertisements) mentioned in methodology

22

Details of each intervention and comparator to allow replication eg. Components of the intervention and comparator, How, when and for how long they were administered etc. mentioned in methodology

23

Any physical or informational materials used as part of the intervention/comparator (e.g., instruction manual) and where the materials can be accessed mentioned in methodology

24

When the comparator group is “usual care”, Description of usual care and Whether the intervention group(s) also received usual care mentioned in methodology

25

Which outcomes are primary and secondary as prespecified in the protocol, Rationale for the choice of trial outcomes mentioned in the methodology and whether they are part of a core outcome set

26

How sample size was determined, including all assumptions (eg. statistical level of significance, statistical power etc.)supporting the sample size calculation mentioned in methodology

27

Explanation of any interim analyses and stopping guidelines mentioned in methodology

28

Who generated the random allocation sequence and the method used mentioned in methodology

29

Type of randomisation and details of any restriction mentioned in methodology(e.g., stratification, blocking and block size) mentioned in the methodology

30

Mechanism used to implement the random allocation sequence (e.g., central computer/telephone; sequentially numbered, sealed containers) mentioned in the menthodology

31

Who enrolled the participants and those who assigned participants to the interventions mentioned in methodology

32

Who was blinded after assignment to interventions (e.g., participants, care providers, outcome assessors, data analysts)

33

Statistical methods used to compare groups for primary and secondary outcomes, including harms

34

The number of participants evaluated for potential enrolment, no. of participants excluded before randomisation with reasons like Declined to participate etc. mentioned in the flow diagram

35

No. of participants Randomly assigned to each group, Who received intervention as allocated in both the groups

36

Intervention and comparator as they were actually administered (e.g.who delivered the intervention/comparator, whether participants adhered, whether they were delivered as intended) mentioned

37

A table showing baseline demographic and clinical characteristics for each group

38

the no. of participants included in the analysis, result for each group, and the estimated effect size and its precision (such as 95% confidence interval) mentioned

39

All harms or unintended events in each group mentioned.

40

Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence mentioned

41

Trial limitations, addressing sources of potential bias, imprecision, generalisability, and, if relevant, multiplicity of analyses mentioned

Voulez-vous vraiment quitter la page ?

En quittant la page, vous perdrez la progression du jeu.